1 Patients were given 1,500,000 international units (IU) of IFN
2 Patients were given 1.8 mg/m(2) inotuzumab ozogamicin intrave
3 Patients were given 10 mg/kg intravenous pembrolizumab every
4 Patients were given 10 mg/kg pembrolizumab every 2 weeks unti
5 Patients were given 1200 mg intravenous atezolizumab every 21
6 Patients were given 250 mg of ciprofloxacin orally twice dail
7 Patients were given 3 mg/kg nivolumab every 2 weeks until dis
8 Patients were given 500 mg of levofloxacin (two 250 mg tablet
9 Patients were given 60 mg of cabozantinib orally per day.
10 In phase 2, 45
patients were given a combination of melflufen plus dexametha
11 uring a median follow-up of 7.7 years (maximum, 19.0), 1273
patients were given a diagnosis of colorectal cancer.
12 10 pediatric patients with surgically repaired EA, 20 (18%)
patients were given a diagnosis of EoE, representing a 364-fo
13 Patients were given a fixed-dose combination tablet of 90 mg
14 When
patients were given a low-dose insulin infusion, insulin sens
15 reliably improved memory compared with control images when
patients were given a recognition-memory test the next day.
16 On discharge from hospital
patients were given a salmeterol/fluticasone inhaler with an
17 Patients were given a structured clinical examination and com
18 All
patients were given a tarsoaponeurectomy as the basic surgica
19 Computer-simulated "
patients" were given a rapid VF (mean deviation [MD]) loss of
20 patients were assessed for eligibility, of which 106 (87%)
patients were given acalabrutinib (14 were treatment naive an
21 Patients were given an oral, once-daily, fixed-dose combinati
22 All
patients were given appropriate supportive intensive care for
23 In the IDegLira group,
patients were given degludec 100 units/mL plus liraglutide 3.
24 Seventy-two
patients were given dexamethasone 40 mg weekly, clarithromyci
25 2135
patients were given disease-specific information about standa
26 Seventy-seven
patients were given DSTP3086S once every 3 weeks, and seven w
27 Between Aug 7, 2015, and Feb 8, 2018, 1100
patients were given either dihydroartemisinin-piperaquine (18
28 Patients were given either oral eplerenone (25 mg/day for 1 w
29 Patients were given first-line cisplatin and gemcitabine chem
30 ious HIT reexposed to heparin 4.4 years (mean) post-HIT; 17
patients were given heparin intraoperatively (without postope
31 90 pen for subcutaneous injection; in the IGlar U100 group,
patients were given IGlar U100 solution, in a 3 mL prefilled
32 In part 2 of GEN501,
patients were given intravenous daratumumab 16 mg/kg once per
33 Patients were given intravenous rituximab 1 g on days 1 and 1
34 Patients were given isavuconazole 200 mg (as its intravenous
35 Patients were given medical therapy (topical and/or systemic)
36 Patients were given nivolumab intravenously over 60 min at 3
37 Twenty
patients were given ombitasvir co-formulated with paritaprevi
38 Patients were given opioids for a mean of 67.9% (SD, 25.0%) o
39 Patients were given oral cannabidiol at 2-5 mg/kg per day, up
40 All
patients were given oral lenalidomide 25 mg per day for 21 of
41 In the phase 1 part of the trial,
patients were given oral ODM-201 at a starting daily dose of
42 A similar percentage (~98%) of
patients were given oral or written radiation safety instruct
43 Patients were given prednisone (10 to 40 mg/d) when the study
44 Most
patients were given radiotherapy with 3-6 months of neoadjuva
45 given a combination of melflufen plus dexamethasone and 13
patients were given single-agent melflufen.
46 Patients were given standard blood schizontocidal treatment a
47 A total of 133
patients were given the CLUSE tool; 16 participants were excl
48 In the dose-expansion phase,
patients were given the recommended dose of the drug combinat
49 Patients were given TPCS2a on day 0 by slow intravenous injec
50 Patients were given up to a maximum of 17 cycles of treatment